RESUMEN
Background: Pharmacotherapy is the mainstay of allergic rhinitis and many caregivers use over-the-counter antihistamines. Bepotastine is a novel oral second generation non-sedative antihistamine and an effective treatment option for allergic rhinitis. The objectives of the present study were to evaluate the efficacy and safety of bepotastine versus cetirizine an over the counter drug.Methods: A prospective, randomized, open-label, parallel-group study was conducted among 60 patients fulfilling the inclusion and exclusion criteria. Group A (n=30) received tablet cetirizine 10 mg once daily and Group B (n=30) received tablet bepotastine 10 mg once daily. Efficacy was assessed by mean change in total symptom score (TSS) which is the sum of total nasal symptom score and total ocular symptom score at the end of two weeks from baseline.Results: At the end of two weeks of treatment, both groups showed statistically significant (p<0.005) improvements from their baseline TSS. Mean TSS was reduced from12.36±2.12 to 4.2±1.66 in group A and from 13.33±3.039 to 3.033±1.40 in Group B. Significant statistical difference in TSS was seen more in Group B than Group A (p<0.005).Conclusions: Both the groups showed a substantial therapeutic benefit in patients with allergic rhinitis, however bepotastine is more effective.